[
    [
        {
            "time": "2021-12-24",
            "original_text": "广生堂：控股子公司与上海药明康德合作开发抗新冠病毒小分子口服药",
            "features": {
                "keywords": [
                    "广生堂",
                    "药明康德",
                    "新冠",
                    "口服药",
                    "3CL蛋白酶抑制剂"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "广生堂：控股子公司与上海药明康德合作开发抗新冠病毒小分子口服药",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-24",
            "original_text": "深交所向广生堂(300436.SZ)发出关注函，要求说明与上海药明康德合作研发的3CL蛋白酶抑制剂的进度 关注函",
            "features": {
                "keywords": [
                    "广生堂",
                    "深交所",
                    "药明康德",
                    "3CL蛋白酶抑制剂",
                    "关注函"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "深交所向广生堂(300436.SZ)发出关注函，要求说明与上海药明康德合作研发的3CL蛋白酶抑制剂的进度 关注函",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-24",
            "original_text": "将与药明康德合作开发新冠口服药，广生堂午盘1分钟内狂拉20cm涨停",
            "features": {
                "keywords": [
                    "广生堂",
                    "药明康德",
                    "新冠",
                    "口服药",
                    "涨停"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "将与药明康德合作开发新冠口服药，广生堂午盘1分钟内狂拉20cm涨停",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 10,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 10,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-12-24",
            "original_text": "药明康德今日大宗交易成交3.96万股，成交价112.03元溢价0.0%",
            "features": {
                "keywords": [
                    "药明康德",
                    "大宗交易",
                    "成交价",
                    "溢价"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德今日大宗交易成交3.96万股，成交价112.03元溢价0.0%",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-24",
            "original_text": "博时基金出海产品表现惨淡，明星经理旗下产品跌幅超20％",
            "features": {
                "keywords": [
                    "博时基金",
                    "出海产品",
                    "跌幅",
                    "明星经理"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "基金"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "博时基金出海产品表现惨淡，明星经理旗下产品跌幅超20％",
                "Correlation": 2,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]